These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35428982)

  • 1. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
    Statland JM; Campbell C; Desai U; Karam C; Díaz-Manera J; Guptill JT; Korngut L; Genge A; Tawil RN; Elman L; Joyce NC; Wagner KR; Manousakis G; Amato AA; Butterfield RJ; Shieh PB; Wicklund M; Gamez J; Bodkin C; Pestronk A; Weihl CC; Vilchez-Padilla JJ; Johnson NE; Mathews KD; Miller B; Leneus A; Fowler M; van de Rijn M; Attie KM
    Muscle Nerve; 2022 Jul; 66(1):50-62. PubMed ID: 35428982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.
    Thomas FP; Brannagan TH; Butterfield RJ; Desai U; Habib AA; Herrmann DN; Eichinger KJ; Johnson NE; Karam C; Pestronk A; Quinn C; Shy ME; Statland JM; Subramony SH; Walk D; Stevens-Favorite K; Miller B; Leneus A; Fowler M; van de Rijn M; Attie KM
    Neurology; 2022 Jun; 98(23):e2356-e2367. PubMed ID: 35545446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.
    Andersen G; Dahlqvist JR; Vissing CR; Heje K; Thomsen C; Vissing J
    J Neurol; 2017 Mar; 264(3):438-447. PubMed ID: 28000006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy.
    Wang LH; Shaw DWW; Faino A; Budech CB; Lewis LM; Statland J; Eichinger K; Tapscott SJ; Tawil RN; Friedman SD
    BMC Musculoskelet Disord; 2021 Mar; 22(1):262. PubMed ID: 33691664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy: Comparison between Facioscapulohumeral Muscular Dystrophy Types 1 and 2.
    Mair D; Huegens-Penzel M; Kress W; Roth C; Ferbert A
    Eur Neurol; 2017; 77(1-2):32-39. PubMed ID: 27855411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial.
    Passerieux E; Hayot M; Jaussent A; Carnac G; Gouzi F; Pillard F; Picot MC; Böcker K; Hugon G; Pincemail J; Defraigne JO; Verrips T; Mercier J; Laoudj-Chenivesse D
    Free Radic Biol Med; 2015 Apr; 81():158-69. PubMed ID: 25246239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging.
    Giacomucci G; Monforte M; Diaz-Manera J; Mul K; Fernandez Torrón R; Maggi L; Marini Bettolo C; Dahlqvist JR; Haberlova J; Camaño P; Gros M; Tartaglione T; Cristiano L; Gerevini S; Calandra P; Deidda G; Giardina E; Sacconi S; Straub V; Vissing J; Van Engelen B; Ricci E; Tasca G
    Eur J Neurol; 2020 Dec; 27(12):2604-2615. PubMed ID: 32697863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound pattern of anterolateral leg muscles in facioscapulohumeral muscular dystrophy.
    Veltsista D; Chroni E
    Acta Neurol Scand; 2021 Aug; 144(2):216-220. PubMed ID: 33844852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative
    Gerhalter T; Marty B; Gast LV; Porzelt K; Heiss R; Uder M; Schwab S; Carlier PG; Nagel AM; Türk M
    J Neurol; 2021 Mar; 268(3):1076-1087. PubMed ID: 33047224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy.
    Hamel J; Lee P; Glenn MD; Burka T; Choi IY; Friedman SD; Shaw DWW; McCalley A; Herbelin L; Dimachkie MM; Lemmers R; van der Maarel SM; Barohn RJ; Tawil R; Statland JM
    Muscle Nerve; 2020 May; 61(5):644-649. PubMed ID: 31884698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.
    Leung DG; Carrino JA; Wagner KR; Jacobs MA
    Muscle Nerve; 2015 Oct; 52(4):512-20. PubMed ID: 25641525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between whole body muscle MRI and functional measures in paediatric patients with facioscapulohumeral muscular dystrophy.
    Woodcock IR; de Valle K; Varma N; Kean M; Ryan MM
    Neuromuscul Disord; 2023 Jan; 33(1):15-23. PubMed ID: 36522253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle MRI findings in facioscapulohumeral muscular dystrophy.
    Gerevini S; Scarlato M; Maggi L; Cava M; Caliendo G; Pasanisi B; Falini A; Previtali SC; Morandi L
    Eur Radiol; 2016 Mar; 26(3):693-705. PubMed ID: 26115655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exome sequencing identifies a novel SMCHD1 mutation in facioscapulohumeral muscular dystrophy 2.
    Mitsuhashi S; Boyden SE; Estrella EA; Jones TI; Rahimov F; Yu TW; Darras BT; Amato AA; Folkerth RD; Jones PL; Kunkel LM; Kang PB
    Neuromuscul Disord; 2013 Dec; 23(12):975-80. PubMed ID: 24128691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasound Imaging of Muscle Contraction of the Tibialis Anterior in Patients with Facioscapulohumeral Dystrophy.
    Gijsbertse K; Goselink R; Lassche S; Nillesen M; Sprengers A; Verdonschot N; van Alfen N; de Korte C
    Ultrasound Med Biol; 2017 Nov; 43(11):2537-2545. PubMed ID: 28764967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
    Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
    Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome.
    Vincenten SCC; Mul K; van As D; Jansen JJ; Heskamp L; Heerschap A; van Engelen BGM; Voermans NC
    J Cachexia Sarcopenia Muscle; 2023 Aug; 14(4):1695-1706. PubMed ID: 37218549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing the role of muscle ultrasound as an imaging biomarker in facioscapulohumeral muscular dystrophy.
    Vincenten SCC; Teeselink S; Voermans NC; van Engelen BGM; Mul K; van Alfen N
    Neuromuscul Disord; 2023 Dec; 33(12):936-944. PubMed ID: 37968164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging.
    Monforte M; Laschena F; Ottaviani P; Bagnato MR; Pichiecchio A; Tasca G; Ricci E
    J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1258-1265. PubMed ID: 31668022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label pilot study of losmapimod to evaluate the safety, tolerability, and changes in biomarker and clinical outcome assessments in participants with facioscapulohumeral muscular dystrophy type 1.
    Kools J; Voermans N; Jiang JG; Mitelman O; Mellion ML; Ramana V; van Engelen BGM
    J Neurol Sci; 2024 Jul; 462():123096. PubMed ID: 38959779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.